Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000149

Drug Information
NameRivastigmine
SynonymsMolPort-003-666-662; HMS2089H18; C11766; (S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; AB1004572; Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester; ENA 713 free base; 123441-03-2; D03822; Carbamic acid, ethylmethyl-, 3-(1-(dimethylamino)ethyl)phenyl ester, (S)-; BIDD:GT0316; 3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate; Exelon; Rivastigmine hydrogen tartrate; 3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate; Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester; 3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; DB00989; Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester; NCGC00167531-01; SDZ 212-713; Rivastigmine (JAN/USAN/INN); UNII-PKI06M3IW0; CHEMBL636; LS-172571; 3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; AC1L2U92; I06-2037; rivastigmine; [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate; m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate; CID77991; Rivastigmine [USAN:INN]
Trade NameExelon
CompanyNorvatis Phamaceuticals Corporation
IndicationAlzheimer's Disease
[ICD9: 331.0   ICD10: G30]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7
-11H,6H2,1-5H3/t11-/m0/s1
InChIKeyXSVMFMHYUFZWBK-NSHDSACASA-N
Canonical SMILESCCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C    
Isomeric SMILESCCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
Therapeutic ClassParasympathomimetics
CAS NumberCAS 123441-03-2
FormulaC14H22N2O2
PubChem Compound IDCID 77991.
PubChem Substance IDSID 13930.
SuperDrug ATC IDN06DA03
SuperDrug CAS ID123441032;
TargetAcetylcholinesteraseInhibitor[2]
Ref 1Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. To Reference
Ref 2From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33. Epub 2009 Jun 5. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543